alendronate has been researched along with Cerebral Palsy in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral alendronate at a dose of 1 mg/kg/week for the treatment of osteopenia in children with cerebral palsy was found to be safe and effective." | 9.16 | Osteopenia in children with cerebral palsy can be treated with oral alendronate. ( Akin, R; Karacalioglu, AO; Karaoglu, A; Paksu, MS; Polat, A; Unay, B; Vurucu, S; Yesilyurt, O, 2012) |
| "Oral alendronate at a dose of 1 mg/kg/week for the treatment of osteopenia in children with cerebral palsy was found to be safe and effective." | 5.16 | Osteopenia in children with cerebral palsy can be treated with oral alendronate. ( Akin, R; Karacalioglu, AO; Karaoglu, A; Paksu, MS; Polat, A; Unay, B; Vurucu, S; Yesilyurt, O, 2012) |
| "Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beecham, E | 1 |
| Candy, B | 1 |
| Howard, R | 1 |
| McCulloch, R | 1 |
| Laddie, J | 1 |
| Rees, H | 1 |
| Vickerstaff, V | 1 |
| Bluebond-Langner, M | 1 |
| Jones, L | 1 |
| Paksu, MS | 1 |
| Vurucu, S | 1 |
| Karaoglu, A | 1 |
| Karacalioglu, AO | 1 |
| Polat, A | 1 |
| Yesilyurt, O | 1 |
| Unay, B | 1 |
| Akin, R | 1 |
1 review available for alendronate and Cerebral Palsy
| Article | Year |
|---|---|
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
1 trial available for alendronate and Cerebral Palsy
| Article | Year |
|---|---|
Osteopenia in children with cerebral palsy can be treated with oral alendronate.
Topics: Absorptiometry, Photon; Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bon | 2012 |